Absci Corporation, trading on the NASDAQ under the symbol ABSI, is a clinical-stage biopharmaceutical company. It focuses on drug discovery using generative AI and a synthetic biology data engine. This innovative approach aims to design advanced therapeutics. Absci is set to participate in the 44th Annual J.P. Morgan Healthcare Conference, showcasing its commitment to breakthrough therapeutics.
On December 17, 2025, H.C. Wainwright maintained its "Buy" rating for Absci, with the stock trading at $3.53. The price target was raised from $7 to $8, as highlighted by TheFly. This reflects confidence in Absci's potential, despite the stock's current price decrease of approximately 0.47%, or $0.016.
Absci's stock has fluctuated between $3.50 and $3.64 during the day. Over the past year, it reached a high of $6.33 and a low of $2.01. The company's market capitalization is approximately $531.3 million. Today's trading volume is 1,367,859 shares on the NASDAQ exchange, indicating active investor interest.
Absci's participation in the J.P. Morgan Healthcare Conference on January 14th is a strategic move. The management will present at 3:45 p.m. Pacific Time, engaging with key stakeholders. Interested parties can access the live and archived webcast through Absci's investor relations website, highlighting transparency and investor engagement.
